Praxis Precision Medicines, Inc.

PRAX Healthcare Biotechnology

Praxis Precision Medicines, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8.6 million, up 249.5% from fiscal 2023.

Revenue
+1,349.1%
EPS
+13.3%
Free cash flow
−43.5%

Quarter to June 2026, against a year earlier

276.75 14.16 +5.39%
Market cap
$7.3B
P/E
0.0×
Fwd P/E
−24.3×
Dividend yield
—
F-score
n/a
Altman Z
19.09
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
5.18 10.22 15.88 15.73
Net Debt/EBITDA
3.38 6.14 7.39 7.78
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(2.96) (3.39) (2.98) (2.70)
Book value per Share
15.63 39.02 48.81 46.03
Free Cash Flow
(65.06) (76.32) (86.21) (78.56)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026